Clinical trials: Lupus Flare
Systemic Lupus Erythematosus
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus
- Trial name
- PLUTO (NCT01649765)
- Testing
- Belimumab 10 mg/kg
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 93 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Lupus Nephritis, Immunosuppression
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week…
- Conditions
- Lupus Nephritis, Immunosuppression, Effect of Drug
- Trial name
- NCT04892212
- Testing
- Sirolimus
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Systemic Lupus Erythematosus, SLE
Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus.
This study aims compare the flare rate of maintenance versus gradual withdrawal of 5 mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent disease.
- Trial name
- NCT06234852
- Testing
- Glucocorticoid withdrawal group, Glucocorticoid maintenance group
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in SLE Patients
Systemic lupus erythematosus (SLE) is a chronic inflammatory systemic autoimmune disease. Recurrent relapses of disease and development of long-term organ damage are two key unsolved clinical problems.
- Trial name
- NCT04515719
- Testing
- Belimumab
- Where
- China
- Volunteers
- 231 people
- Sponsor
- RenJi Hospital
Lupus Nephritis
Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)
At this moment, the duration of the treatment in Proliferative Lupus Nephritis has not been determined. Almost 30 percent of patients in total remission during or after a treatment, will relapse in the first 5 years.
- Trial name
- LuFla (NCT02313974)
- Testing
- Renal Biopsy
- Where
- Argentina
- Volunteers
- 36 people
- Sponsor
- Hospital de Clinicas José de San Martín
Systemic Lupus Erythematosus
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
This study provides subjects who complete the BEL113750 study and subjects who complete the open-label extension of HGS1006-C1115 (referred to as C1115) Study in Japan the option of continuing treatment with belimumab (10 mg/kg…
- Trial name
- NCT01597622
- Testing
- Belimumab
- Where
- 27 sites in Japan, South Korea
- Volunteers
- 142 people
- Sponsor
- GlaxoSmithKline
Lupus Nephritis, Systemic Lupus Erythematosus
Biomarker Development for Autoimmune Disorders Involving the Kidneys
SILENT-LN is a prospective observational cohort study of adults with systemic lupus erythematosus, including participants with no renal involvement, suspected renal involvement, active lupus nephritis, previous lupus nephritis…
- Trial name
- SILENT_LN (NCT07666711)
- Testing
- Longitudinal Blood and Urine Biomarker Monitoring
- Where
- Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
System; Lupus Erythematosus
FLARE Lupus Research Study Systemic Lupus Erythematosus
The first phase of this pilot study will assess changes in quality of life at the end of a 16-week Mymee program in patients with moderate to severe SLE.
- Trial name
- FLARE (NCT03426384)
- Testing
- Mymee Program
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mymee Inc.
Systemic Lupus Erythematosus
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Hypothesis: A reason for repeated disappointing outcomes of clinical trials testing targeted immune biologics for lupus may be the heterogeneity of the disease, exacerbated by the variable effects on immune homeostasis of the…
- Trial name
- BOLD (NCT00987831)
- Testing
- Group B SLE one blood donation, Blood drawing only Group C, Group A SLE prospective study
- Where
- 2 sites in United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
H. Pylori, SLE - Systemic Lupus Erythematosus
Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians
A cross-sectional, observational study aims to evaluate the relationship between Helicobacter pylori infection and disease activity in patients diagnosed with systemic lupus erythematosus (SLE), using a combination of structured…
- Trial name
- NCT07157202
- Volunteers
- 115 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus.
- Trial name
- DARE (NCT01781611)
- Testing
- extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Oklahoma Medical Research Foundation
Systemic Lupus Erthematosus, Lupus Glomerulonephritis
Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
The study explores the role of the colour Doppler scanning of the renal arteries and its relation to the degree of disease affection in lupus nephritis
- Conditions
- Systemic Lupus Erthematosus, Lupus Glomerulonephritis, Lupus Flare
- Trial name
- NCT06757725
- Testing
- colour doppler of the renal artery and measurement of resistive index
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
System; Lupus Erythematosus, Lupus Erythematosus
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
This study is investigating the development of a diagnostic test intended to predict flares in patients with Systemic Lupus Erythematosus.
- Conditions
- System; Lupus Erythematosus, Lupus Erythematosus, SLE, Lupus Flare
- Trial name
- TOTAL FEEDBACK (NCT04018222)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Progentec Diagnostics, Inc.
Systemic Lupus Erythematosus, Lupus
Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization
To develop a test to characterize and monitor SLE disease activity status from a participant's home by analyzing the gene expression from participant self-collected blood samples using a novel fingerstick collection kit.
- Conditions
- Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Erythematosus, Systemic
- Trial name
- LIFT (NCT03142412)
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- DxTerity Diagnostics
Lupus Erythematosus
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus
Given that GADD34 has been described as a potential key regulator of pro-inflammatory cytokine production in human and elevated blood marker in SLE patients, this study aim to prove that the GADD34 RNA level in mononuclear blood…
- Trial name
- GADD34-LES (NCT02455089)
- Testing
- GADD34 RNA level measurement.
- Where
- 7 sites in France
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Lupus Nephritis
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
The study will investigate the efficacy and safety of enteric-coated mycophenolate sodium in combination with two different corticosteroid (CS) regimes for the induction of remission of a lupus nephritis flare.
- Trial name
- NCT00423098
- Testing
- Mycophenolate sodium, Prednisone, Methylprednisolone
- Where
- 17 sites in Colombia, France and 7 more
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.
- Trial name
- NCT01345253
- Testing
- Belimumab
- Where
- 47 sites in China, Japan and 1 more
- Volunteers
- 709 people
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus, Systemic
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of…
- Trial name
- APRIL-SLE (NCT00624338)
- Testing
- Atacicept 75 mg, Atacicept 150 mg
- Where
- 113 sites in United States, Argentina and 27 more
- Volunteers
- 461 people
- Sponsor
- EMD Serono